Comparing two treatments for head and neck cancer before chemoradiation
Treatments studied
Part of Cancer, Ear, nose & throat clinical trials.
This trial tests two different drug combos—one using an EGFR-targeted therapy alone, the other adding an immunotherapy—before standard chemoradiation for locally advanced head and neck cancer. The goal is to see which approach works better without prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have head and neck cancer that is locally advanced (not spread to distant parts of the body).
- You need to be in good enough health to have a daily activity level of 0 or 1 on a standard scale (able to do light work).
- Your tumor must be measurable on a CT scan or MRI.
- You must be able to receive cisplatin chemotherapy (a common treatment for head and neck cancer).
- You should not have significant hearing loss (at most mild hearing trouble).
- You must not have had any prior chemotherapy, immunotherapy, targeted therapy, or radiation for head and neck cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether combining radiation therapy with immunotherapy works better than immunotherapy alone for advanced head and neck cancer that hasn't been treated before. The goal is to help your body's immune system fight the cancer more effectively.
This trial is for people with advanced head and neck cancer that has not been treated yet. It tests a combination of an immunotherapy drug (Pucotenlimab) and chemotherapy given before surgery to see if it can shrink tumors and improve outcomes.
This trial tests whether a combination of two drugs (Becotatug Vedotin and Putlimab) before surgery and then radiation after surgery can help people with locally advanced head and neck squamous cell carcinoma. It aims to see if this approach is safe and effective.
This trial tests a combination of three drugs (MRG003, pucotenlimab, and possibly cisplatin) given before surgery for people with a specific type of head and neck cancer that is EGFR-positive and has not been treated yet. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether two new drugs (becotatug vedotin and pucotenlimab) work better than standard surgery and radiation for locally advanced oral or oropharyngeal squamous cell carcinoma. The drugs are given before surgery to shrink the tumor.
This trial tests a combination of three drugs (docetaxel, nimotuzumab, and pucotenlimab) for people with head and neck cancer that has come back or spread. It is for those who have already tried and failed treatments like immunotherapy and platinum chemotherapy.
Hear when a new Locally Advanced Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.